{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:10:58Z","timestamp":1780330258638,"version":"3.54.1"},"reference-count":34,"publisher":"China Science Publishing & Media Ltd.","issue":"3","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.3724\/abbs.2025144","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T07:55:21Z","timestamp":1754985321000},"page":"649-662","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target"],"prefix":"10.3724","volume":"58","author":[{"given":"Jianming","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjia","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongding","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingke","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouda","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weide","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000524892","volume":"95","author":"Paschoalin VP","year":"2022","unstructured":"Paschoalin VP, Tucci J\u00fanior S, G. Estevanato A, B. Tiraboschi R, Antonini SR, Muglia VF, Chahud F. Histopathological criteria for paediatric adrenocortical carcinoma. Horm Res Paediatr, 2022, 95: 347-353.","journal-title":"Horm Res Paediatr"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/MED.0000000000000056","volume":"21","author":"Terzolo M","year":"2014","unstructured":"Terzolo M, Zaggia B, Allasino B, De Francia S. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obesity, 2014, 21: 159-165.","journal-title":"Curr Opin Endocrinol Diabetes Obesity"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"Else T","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S. Adrenocortical carcinoma. Endocrine Rev, 2014, 35: 282-326.","journal-title":"Endocrine Rev"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1210\/jc.2013-2856","volume":"99","author":"Else T","year":"2014","unstructured":"Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2014, 99: 455-461.","journal-title":"J Clin Endocrinol Metab"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"Fassnacht M","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger RR, Haak HR. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors. Eur J Endocrinol, 2018, 179: G1-G46.","journal-title":"Eur J Endocrinol"},{"key":"CITATION6","unstructured":"LiverTox: clinical and research information on drug-induced liver injury.  National Institute of Diabetes and Digestive and Kidney Diseases  2012."},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/jcm8111850","volume":"8","author":"Puglisi S","year":"2019","unstructured":"Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Simeoli C, Torlontano M. Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment. J Clin Med, 2019, 8: 1850.","journal-title":"J Clin Med"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"113424","DOI":"10.1016\/j.ejca.2023.113424","volume":"196","author":"Debets P","year":"2024","unstructured":"Debets P, Dreijerink KMA, Engelsman A, Dahele M, Haak HR, Steenaard RV, Kapiteijn E. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study. Eur J Cancer, 2024, 196: 113424.","journal-title":"Eur J Cancer"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/cancers13081798","volume":"13","author":"Georgantzoglou N","year":"2021","unstructured":"Georgantzoglou N, Kokkali S, Tsourouflis G, Theocharis S. Tumor microenvironment in adrenocortical carcinoma: barrier to immunotherapy success?. Cancers, 2021, 13: 1798.","journal-title":"Cancers"},{"key":"CITATION10","doi-asserted-by":"crossref","unstructured":"Cheng J, He Z, Jing J, Liu Y, Zhang H. Integrating machine learning and multi-omics to identify key SUMOylation molecular signature in sarcoma.  Life Conflux , 2024, 1: e88.","DOI":"10.71321\/lcflx.00001"},{"key":"CITATION11","doi-asserted-by":"crossref","unstructured":"Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification.  Histopathology  2009, 55: 535\u2013543.","DOI":"10.1111\/j.1365-2559.2009.03423.x"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41379-018-0042-6","volume":"31","author":"Vatrano S","year":"2018","unstructured":"Vatrano S, Volante M, Duregon E, Giorcelli J, Izzo S, Rapa I, Votta A. Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. Modern Pathol, 2018, 31: 1257-1269.","journal-title":"Modern Pathol"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5146\/tjpath.2015.01317","volume":"31","author":"Duregon E","year":"2015","unstructured":"Duregon E, Volante M, Rapa I, No SV, Potti MP. Dissecting morphological and molecular heterogeneity in adrenocortical carcinoma. Turk Patoloji Derg, 2015, 31: 98-104.","journal-title":"Turk Patoloji Derg"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"Bougeard G","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M. Revisiting li-fraumeni syndrome from TP53 mutation carriers. J Clin Oncol, 2015, 33: 2345-2352.","journal-title":"J Clin Oncol"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0163-7258(89)90108-3","volume":"41","author":"Osheroff N","year":"1989","unstructured":"Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther, 1989, 41: 223-241.","journal-title":"Pharmacol Ther"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/nar\/gkn994","volume":"37","author":"Roca J","year":"2009","unstructured":"Roca J. Topoisomerase II: a fitted mechanism for the chromatin landscape. Nucleic Acids Res, 2009, 37: 721-730.","journal-title":"Nucleic Acids Res"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13046-023-02855-2","volume":"42","author":"Wang K","year":"2023","unstructured":"Wang K, Jiang X, Jiang Y, Liu J, Du Y, Zhang Z, Li Y. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A. J Exp Clin Cancer Res, 2023, 42: 320.","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12935-019-0956-1","volume":"19","author":"Ma W","year":"2019","unstructured":"Ma W, Wang B, Zhang Y, Wang Z, Niu D, Chen S, Zhang Z. Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis. Cancer Cell Int, 2019, 19: 239.","journal-title":"Cancer Cell Int"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/jnci\/djp067","volume":"101","author":"O\u2032Malley FP","year":"2009","unstructured":"O\u2032Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. JNCI J Natl Cancer Institute, 2009, 101: 644-650.","journal-title":"JNCI J Natl Cancer Institute"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/ERC-12-0403","volume":"20","author":"Jain M","year":"2013","unstructured":"Jain M, Zhang L, He M, Zhang YQ, Shen M, Kebebew E. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer, 2013, 20: 361-370.","journal-title":"Endocr Relat Cancer"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"216739","DOI":"10.1016\/j.canlet.2024.216739","volume":"588","author":"Yin W","year":"2024","unstructured":"Yin W, Chen G, Li Y, Li R, Jia Z, Zhong C, Wang S. Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: a benchmarking study using ten machine learning methods and twelve patient cohorts. Cancer Lett, 2024, 588: 216739.","journal-title":"Cancer Lett"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.7150\/ijbs.77133","volume":"19","author":"Zhong C","year":"2023","unstructured":"Zhong C, Long Z, Yang T, Wang S, Zhong W, Hu F, Teoh JYC. M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy. Int J Biol Sci, 2023, 19: 1543-1563.","journal-title":"Int J Biol Sci"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1371\/journal.pone.0001195","volume":"2","author":"Hoshida Y","year":"2007","unstructured":"Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP, Hofmann O. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS ONE, 2007, 2: e1195.","journal-title":"PLoS ONE"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"Roh W","year":"2017","unstructured":"Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med, 2017, 9: eaah3560.","journal-title":"Sci Transl Med"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"e172716","DOI":"10.1172\/JCI172716","volume":"134","author":"Chen Z","year":"2024","unstructured":"Chen Z, Vallega KA, Wang D, Quan Z, Fan S, Wang Q, Leal T. DNA topoisomerase II inhibition potentiates osimertinib\u2019s therapeutic efficacy in EGFR-mutant non\u2013small cell lung cancer models. J Clin Invest, 2024, 134: e172716.","journal-title":"J Clin Invest"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1039\/d1dt03700e","volume":"51","author":"Zhang H","year":"2022","unstructured":"Zhang H, Wang Y, Wang Y, Han Q, Yan H, Yang T, Guo Z. Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase II\u03b1 in cancer cells. Dalton Trans, 2022, 51: 3188-3197.","journal-title":"Dalton Trans"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","volume":"15","author":"Crona J","year":"2019","unstructured":"Crona J, Beuschlein F. Adrenocortical carcinoma\u2014towards genomics guided clinical care. Nat Rev Endocrinol, 2019, 15: 548-560.","journal-title":"Nat Rev Endocrinol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"e0231665","DOI":"10.1371\/journal.pone.0231665","volume":"15","author":"Ikeya A","year":"2020","unstructured":"Ikeya A, Nakashima M, Yamashita M, Kakizawa K, Okawa Y, Saitsu H, Sasaki S. CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant. PLoS ONE, 2020, 15: e0231665.","journal-title":"PLoS ONE"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1097\/CM9.0000000000001075","volume":"133","author":"Lyu WJ","year":"2020","unstructured":"Lyu WJ, Shu YJ, Liu YB, Dong P. Topoisomerase II alpha promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin signaling pathway. Chin Med J, 2020, 133: 2321-2329.","journal-title":"Chin Med J"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"2325126","DOI":"10.1080\/15384047.2024.2325126","volume":"25","author":"Zhang K","year":"2024","unstructured":"Zhang K, Zheng X, Sun Y, Feng X, Wu X, Liu W, Gao C. TOP2A modulates signaling via the AKT\/mTOR pathway to promote ovarian cancer cell proliferation. Cancer Biol Ther, 2024, 25: 2325126.","journal-title":"Cancer Biol Ther"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cancers14041070","volume":"14","author":"Karagianni F","year":"2022","unstructured":"Karagianni F, Piperi C, Casar B, de la Fuente-Vivas D, Garc\u00eda-G\u00f3mez R, Lampadaki K, Pappa V. Combination of resminostat with ruxolitinib exerts antitumor effects in the chick embryo chorioallantoic membrane model for cutaneous T cell lymphoma. Cancers, 2022, 14: 1070.","journal-title":"Cancers"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","volume":"83","author":"Crozier L","year":"2023","unstructured":"Crozier L, Foy R, Adib R, Kar A, Holt JA, Pareri AU, Valverde JM. CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence. Mol Cell, 2023, 83: 4062-4077.e5.","journal-title":"Mol Cell"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1158\/1078-0432.CCR-20-0887","volume":"26","author":"Centanni M","year":"2020","unstructured":"Centanni M, Krishnan SM, Friberg LE. Model-based dose individualization of sunitinib in gastrointestinal stromal tumors. Clin Cancer Res, 2020, 26: 4590-4598.","journal-title":"Clin Cancer Res"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","volume":"80","author":"M\u00e9jean A","year":"2021","unstructured":"M\u00e9jean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, Thiery-Vuillemin A. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?. Eur Urology, 2021, 80: 417-424.","journal-title":"Eur Urology"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/C03B6A26392A40AC9997D4BE8B478796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025144","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/C03B6A26392A40AC9997D4BE8B478796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:18:41Z","timestamp":1775204321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,27]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025144","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}